Aerovate Therapeutics (AVTE) Short Interest Ratio & Short Volume → This unknown company solves the biggest issue with AI (From Manward Press) (Ad) Free AVTE Stock Alerts $21.01 +1.73 (+8.97%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Aerovate Therapeutics Short Interest DataCurrent Short Volume1,880,000 sharesPrevious Short Volume1,250,000 sharesChange Vs. Previous Month+50.40%Dollar Volume Sold Short$37.62 millionShort Interest Ratio / Days to Cover13.1Last Record DateApril 30, 2024Outstanding Shares27,900,000 sharesFloat Size18,030,000 sharesShort Percent of Float10.43%Today's Trading Volume333,631 sharesAverage Trading Volume134,305 sharesToday's Volume Vs. Average248% Short Selling Aerovate Therapeutics ? Sign up to receive the latest short interest report for Aerovate Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAVTE Short Interest Over TimeAVTE Days to Cover Over TimeAVTE Percentage of Float Shorted Over Time Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. Aerovate Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20241,880,000 shares $37.62 million +50.4%10.4%13.1 $20.01 4/15/20241,250,000 shares $31.63 million +25.9%7.2%8.3 $25.30 3/31/2024993,100 shares $29.37 million +9.9%5.8%7.6 $29.57 3/15/2024903,700 shares $24.13 million -10.5%5.3%8.8 $26.70 2/29/20241,010,000 shares $23.31 million -9.8%5.9%10.7 $23.08 2/15/20241,120,000 shares $24.24 million +5.7%6.6%11.7 $21.64 Get the Latest News and Ratings for AVTE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20241,060,000 shares $20.47 million +11.3%6.2%11.8 $19.31 1/15/2024952,100 shares $19.13 million -0.8%5.6%12.6 $20.09 12/31/2023959,300 shares $21.71 million -12.0%5.6%11.7 $22.63 12/15/20231,090,000 shares $19.62 million -10.7%6.4%13.2 $18.00 11/30/20231,220,000 shares $19.17 million -5.4%7.2%16.1 $15.71 11/15/20231,290,000 shares $18.80 million +4.9%7.6%17.8 $14.57 10/31/20231,230,000 shares $13.05 million -8.9%7.1%16.9 $10.61 10/15/20231,350,000 shares $14.85 million -12.3%7.8%18.3 $11.00 9/30/20231,540,000 shares $20.90 million +7.7%8.9%21.3 $13.57 9/15/20231,430,000 shares $18.80 million +5.9%8.3%20 $13.15 8/31/20231,350,000 shares $21.45 million +3.9%7.8%15.9 $15.89 8/15/20231,300,000 shares $19.21 million +4.8%7.5%14.6 $14.78 7/31/20231,240,000 shares $21.64 million +2.5%7.3%14.8 $17.45 7/15/20231,210,000 shares $22.08 million +9.0%7.1%13.9 $18.25 6/30/20231,110,000 shares $19.04 million No Change6.5%12.6 $17.15 6/15/20231,110,000 shares $18.76 million +15.4%6.5%12.2 $16.90 5/31/2023961,900 shares $15.63 million +5.3%6.2%12.3 $16.25 5/15/2023913,900 shares $19.27 million -5.3%5.9%12.6 $21.08 4/30/2023965,000 shares $20.24 million +1.4%6.1%13.5 $20.97 4/15/2023951,300 shares $16.07 million +10.2%6.0%10.3 $16.89 3/31/2023862,900 shares $17.40 million -7.4%5.5%8.9 $20.17 3/15/2023932,200 shares $20.49 million -4.4%5.6%9.6 $21.98 2/28/2023974,600 shares $23.95 million +1.5%5.9%7.2 $24.57 2/15/2023960,000 shares $25.32 million -53.2%5.8%6.3 $26.37 1/31/20232,050,000 shares $46.84 million +0.5%12.4%13 $22.85 1/15/20232,040,000 shares $51.10 million +9.1%12.3%15.5 $25.05 12/30/20221,870,000 shares $54.79 million +11.3%11.3%14.9 $29.30 12/15/20221,680,000 shares $43.09 million +33.3%10.3%13.7 $25.65 11/30/20221,260,000 shares $23.74 million -14.3%7.7%12.2 $18.84 11/15/20221,470,000 shares $28.62 million -3.3%9.0%17.2 $19.47 10/31/20221,520,000 shares $29.66 million +0.7%9.1%21 $19.51 10/15/20221,510,000 shares $29.25 million +2.0%9.1%18 $19.37 9/30/20221,480,000 shares $24.54 million -1.3%8.9%14.4 $16.58 9/15/20221,500,000 shares $23.76 million No Change9.0%13.7 $15.84Wall Street legend who predicted 2021 tech crash issues new warning (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history.Watch his stock warning right here, 100% free of charge AVTE Short Interest - Frequently Asked Questions What is Aerovate Therapeutics' current short interest? Short interest is the volume of Aerovate Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 1,880,000 shares of AVTE short. 10.43% of Aerovate Therapeutics' shares are currently sold short. Learn More on Aerovate Therapeutics' current short interest. What is a good short interest ratio for Aerovate Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AVTE shares currently have a short interest ratio of 13.0. Learn More on Aerovate Therapeutics's short interest ratio. What is a good short interest percentage for Aerovate Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.43% of Aerovate Therapeutics' floating shares are currently sold short. Is Aerovate Therapeutics' short interest increasing or decreasing? Aerovate Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,880,000 shares, an increase of 50.4% from the previous total of 1,250,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Aerovate Therapeutics' float size? Aerovate Therapeutics currently has issued a total of 27,900,000 shares. Some of Aerovate Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aerovate Therapeutics currently has a public float of 18,030,000 shares. How does Aerovate Therapeutics' short interest compare to its competitors? 10.43% of Aerovate Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Aerovate Therapeutics: IGM Biosciences, Inc. (29.87%), Avid Bioservices, Inc. (17.42%), Applied Therapeutics, Inc. (3.91%), Astria Therapeutics, Inc. (10.24%), Phathom Pharmaceuticals, Inc. (41.92%), Arbutus Biopharma Co. (3.08%), COMPASS Pathways plc (4.99%), Calliditas Therapeutics AB (publ) (0.03%), Larimar Therapeutics, Inc. (6.11%), Stoke Therapeutics, Inc. (15.94%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Aerovate Therapeutics stock? Short selling AVTE is an investing strategy that aims to generate trading profit from Aerovate Therapeutics as its price is falling. AVTE shares are trading up $1.50 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Aerovate Therapeutics? A short squeeze for Aerovate Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AVTE, which in turn drives the price of the stock up even further. How often is Aerovate Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AVTE, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: IGM Biosciences Short Interest Data Avid Bioservices Short Interest Data Applied Therapeutics Short Interest Data Astria Therapeutics Short Interest Data Phathom Pharmaceuticals Short Interest Data Arbutus Biopharma Short Interest Data COMPASS Pathways Short Interest Data Calliditas Therapeutics AB (publ) Short Interest Data Larimar Therapeutics Short Interest Data Stoke Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AVTE) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper